We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

BioRelix and Dalton Medicinal Chemistry Sign Research Agreement to Capitalize on RiboSwitch Technology

News   Nov 14, 2007

 
BioRelix and Dalton Medicinal Chemistry Sign Research Agreement to Capitalize on RiboSwitch Technology
 
 
 

RELATED ARTICLES

Concern Over Fake ISO 9001 Accreditation of Chinese Companies

News

A study concludes that fake ISO 9001 quality certificates are very widespread across Chinese companies and that the certification processes of the auditing companies lack credibility.

READ MORE

Protein Prods Cancer-fighting T Cells

News

A new protein has been created that mimics the action of a key immune regulatory protein, interleukin 2 (IL-2). IL-2 is a potent anticancer drug and an effective treatment for autoimmune disease, but its toxic side effects have limited its clinical usefulness.

READ MORE

Diversifying Drug Development with New Metal Catalyst

News

A team of researchers has developed a new manganese-based catalyst that can change the structure of drug-like molecules to make new drugs, advancing the pace and efficiency of drug development.

READ MORE

 

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE